Environmental Benefit Seen With GLP-1 Receptor Agonist Use in Heart Failure
By Elana Gotkine HealthDay Reporter
FRIDAY, Aug. 29, 2025 -- Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG) emissions per patient per year, according to a study presented at the European Society of Cardiology Congress 2025, held from Aug. 29 to Sept. 1 in Madrid.
Bhargav Makwana, M.B.B.S., from the Lahey Clinic Medical Center in Burlington, Massachusetts, and colleagues examined the environmental benefits of GLP-1 RA therapy for reducing GHG emissions associated with worsening heart failure events. Data on the worsening of heart failure events with GLP-1 RAs and placebo were obtained from an individual patient-level meta-analysis of four randomized controlled trials involving patients with heart failure with preserved ejection fraction.
The researchers identified 54 worsening heart failure events among 1,914 patients receiving GLP-1 RAs compared with 86 events among 1,829 patients receiving placebo. Heart failure event-related GHG emissions were estimated to be 9.45 and 9.70 kg CO2e per patient per year among GLP-1 RA and placebo users, respectively, arising predominantly from inpatient stays and outpatient visits. Per patient per year, GLP-1 RA users had about 695.33 kg CO2e lower emissions due to a reduction in daily calorie consumption compared with placebo users.
"0.25 kg of CO2-equivalent per person saved annually from reduced hospitalizations might sound small," lead author Sarju Ganatra, M.D., from Lahey Hospital, said in a statement. "However, when this figure is scaled up to the millions of patients eligible for these therapies, it adds up to over 2 billion kilograms of CO2-equivalent saved."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
Variables Associated With Heart Failure Compared for Men and Women
THURSDAY, Aug. 28, 2025 -- Asthma, depression, anxiety, and hypothyroidism are associated with heart failure with preserved ejection fraction (HFpEF) and heart failure with...
Overweight Status Appears to Reduce Mortality in Seniors Undergoing Elective Surgery
THURSDAY, Aug. 28, 2025 -- Older adults (aged 65 years and older) with overweight who undergo elective surgery have a lower rate of 30-day all-cause mortality compared with those...
Spironolactone Does Not Reduce Risk for Cardiovascular Morbidity, Mortality in Patients on Dialysis
THURSDAY, Aug. 28, 2025 -- Spironolactone does not reduce a composite outcome of cardiovascular mortality and hospitalization due to heart failure among patients receiving...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.